Discovering targeted
medicines

Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis

Drug discovery with a strong track record

Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. We have built an attractive portfolio of assets and have a strong track record of drug discovery. Our drug discovery engine has delivered five molecules to clinical stage development, and we have completed a number of major partnering transactions in recent years. Our portfolio includes two Phase 2 assets; RXC004, a Porcupine inhibitor targeting Wnt-ligand dependent tumours and RXC007, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis, as well as a pipeline of rapidly advancing research programs and collaborations, driven by our world-class drug discovery engine.

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Phase 3

Upcoming Milestones

Oncology

Porcupine Inhibitor
(RXC004)

Find out more

Genetically selected MSS mCRC mono + nivolumab combo

Porcupine

Topline data – from H1 2023

Genetically selected pancreatic cancer monotherapy Biliary cancer monotherapy + anti-PD-1 combination

Porcupine2
Fibrosis

ROCK2 Selective Inhibitor
(RXC007)

Find out more

Idiopathic pulmonary fibrosis (IPF)

Phase 2a topline data – H2 2023

GI-targeted ROCK Inhibitor
(RXC008)

Find out more

Fibrostenotic Crohn’s Disease

IND/CTA submission – end 2023

Discovery Engine

DDR Inhibitor
(Discoidin Domain Receptor)

Find out more

Fibrosis, Cancer-associated fibrosis

Progress programmes – target of 2 IND’s by 2025

Research Targets
(Wholly-owned)

Oncology & Fibrosis

Partnered

Porcupine Inhibitor
(RXC006/AZD5055)

Find out more

Idiopathic pulmonary fibrosis (IPF)

Licensed to AstraZeneca

Pan-RAF Inhibitor
(JZP815)

Find out more

Oncology

Sold to Jazz Pharmaceuticals

MAPK Pathway
Target

Oncology

Progress Jazz Collaboration

DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase

Our Pipeline

Oncology

Porcupine Inhibitor
(RXC004)

Porcupine
Phase 2

Genetically selected MSS mCRC mono + nivolumab combo

Read more

UPCOMING MILESTONES

Topline data – from H1 2023

Porcupine2
Phase 2

Genetically selected pancreatic cancer monotherapy Biliary cancer monotherapy + anti-PD-1 combination

Fibrosis

ROCK2 Selective Inhibitor
(RXC007)

Phase 2

Idiopathic pulmonary fibrosis (IPF)

Read more

UPCOMING MILESTONES

Phase 2a topline data – H2 2023

GI-targeted ROCK Inhibitor
(RXC008)

Preclinical

Fibrostenotic Crohn’s Disease

Read more

UPCOMING MILESTONES

IND/CTA submission – end 2023

Discovery Engine

DDR Inhibitor
(Discoidin Domain Receptor)

Research

Fibrosis, Cancer-associated fibrosis

Read more

UPCOMING MILESTONES

Progress programmes – target of 2 IND’s by 2025

Research Targets
(Wholly-owned)

Research

Oncology & Fibrosis

Partnered

Porcupine Inhibitor
(RXC006/AZD5055)

Preclinical

Idiopathic pulmonary fibrosis (IPF)

Read more

UPCOMING MILESTONES

Licensed to AstraZeneca

Pan-RAF Inhibitor
(JZP815)

Phase 1

Oncology

Read more

UPCOMING MILESTONES

Sold to Jazz Pharmaceuticals

MAPK Pathway
Target

Research

Oncology

UPCOMING MILESTONES

Progress Jazz Collaboration

DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase

Our values

At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.

Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need.

Underpinning our work are our five core company values that underline in everything we do: